The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-30 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
=== Protection === The lungs possess several characteristics which protect against infection. The respiratory tract is lined by respiratory epithelium or respiratory mucosa, with hair-like projections called cilia that beat rhythmically and carry mucus. This mucociliary clearance is an important defence system against air-borne infection. The dust particles and bacteria in the inhaled air are caught in the mucosal surface of the airways, and are moved up towards the pharynx by the rhythmic upward beating action of the cilia. The lining of the lung also secretes immunoglobulin A which protects against respiratory infections; goblet cells secrete mucus which also contains several antimicrobial compounds such as defensins, antiproteases, and antioxidants. The size of the respiratory tract and the flow of air also protect the lungs from larger particles. Smaller particles deposit in the mouth and behind the mouth in the oropharynx, and larger particles are trapped in nasal hair after inhalation.
Therefore, typical PMF samples are isolated proteins from two-dimensional gel electrophoresis (2D gels) or isolated SDS-PAGE bands. Additional analyses by MS/MS can either be direct, e.g., MALDI-TOF/TOF analysis or downstream nanoLC-ESI-MS/MS analysis of gel spot eluates.
It was, unlike the first film, a true representation of Judge Dredd ... Karl Urban was a fine Dredd and I'd be more than happy to see him in the follow-up. Olivia Thirlby excelled as Anderson ... The character and storyline are pure Dredd." Dredd has been recognised as a cult film since its release. Some reviewers drew comparisons between Dredd and The Raid: Redemption, another action film released a few months earlier, noting that similar elements in setting, story, and characters made Dredd appear derivative. However, Garland and Urban explained that the timing of when the films were shot would have made plagiarism impossible.
=== Cystic fibrosis === Cystic fibrosis (CF) was first added to newborn screening programs in New Zealand and regions of Australia in 1981, by measuring immunoreactive trypsinogen (IRT) in dried blood spots. After the CFTR gene was identified, Australia introduced a two tier testing program to reduce the number of false positives. Samples with an elevated IRT value were then analyzed with molecular methods to identify the presence of disease causing mutations before being reported back to parents and health care providers. CF is included in the core panel of conditions recommended for inclusion in all 50 states, Texas was the last state to implement their screening program for CF in 2010. Alberta was the first Canadian province to implement CF screening in 2007. Quebec, New Brunswick, Nova Scotia, Newfoundland and Prince Edward Island do not include CF in their screening programs. The United Kingdom as well as many European Union countries screen for CF as well. Switzerland is one of the latest countries to add CF to their newborn screening menu, doing so in January 2011.
Sources: en.wikipedia.org
== Mitigation efforts == The ASHP recommended expedited reviews for new generic drug manufacturing companies, and recommended regular and publicly released inspection reports to provide purchasers with information on present difficulties or issues in manufacturing, and to inform buyers of companies with production or compliance issues. It also recommended amendments to Section 510(j) of the Federal Food, Drug, and Cosmetics Act to introduce non-negligible penalties on drug manufacturers that lack plans for managing production or supply chain difficulties and who do not keep track of or release data related to production and supply chain metrics. The United States Department of Health and Human Services adopted these recommendations in a white paper outlining policy proposals for future laws and amendments. The paper also recommended penalties for hospitals that did not follow "HHS-required inventory and purchasing practices", which the ASHP stating that such penalties could negatively impact lesser-financed hospitals more susceptible to drug shortages by preventing them from investing in means to mitigate shortages.
One chromatography technique based on molecular properties is usually not sufficient in obtaining a protein of high purity. In addition to size, ion exchange chromatography separates compounds according to the nature and degree of their ionic charge. The column to be used is selected according to its type and strength of charge. Anion exchange resins have a positive charge and are used to retain and separate negatively charged compounds (anions), while cation exchange resins have a negative charge and are used to separate positively charged molecules (cations). Before the separation begins a buffer is pumped through the column to equilibrate the opposing charged ions. Upon injection of the sample, solute molecules will exchange with the buffer ions as each competes for the binding sites on the resin. The length of retention for each solute depends upon the strength of its charge. The most weakly charged compounds will elute first, followed by those with successively stronger charges. Because of the nature of the separating mechanism, pH, buffer type, buffer concentration, and temperature all play important roles in controlling the separation. Ion exchange chromatography is a very powerful tool for use in protein purification and is frequently used in both analytical and preparative separations. It is especially useful when purifying nucleic-acid binding proteins, where separation of the protein from the bound nucleic acid is required to obtain a pure sample devoid of nucleic acids co-purified from the expression system or the native source.
called Duck and Cover, in which a turtle demonstrates how to protect oneself from the immediate effects of an atomic bomb explosion by using a coat, tablecloths, or even a newspaper. Recognizing that existing medical capacity would not be sufficient in an emergency, dentists were called upon to either assist physicians in an emergency or, if necessary, to provide assistance themselves. To mobilize the profession with the help of a prominent representative, dentist Russell Welford Bunting (1881-1962), dean of the University of Michigan Dental School, was recruited in July 1951 as a dental consultant to the USFCDA. The American physicist Karl Ziegler Morgan (1907-1999) was one of the founders of radiation health physics. In later life, after a long career with the Manhattan Project and Oak Ridge National Laboratory (ORNL), he became a critic of nuclear power and nuclear weapons production. Morgan was Director of Health Physics at ORNL from the late 1940s until his retirement in 1972. In 1955, he became the first president of the Health Physics Society and served as editor of the journal Health Physics from 1955 to 1977. Nuclear fallout shelters are designed to protect for an extended period. Due to the nature of nuclear warfare, such shelters must be completely self-sufficient for long periods. In particular, because of the radioactive contamination of the surrounding area, such a facility must be able to survive for several weeks. In 1959, top-secret construction began in Germany on a government bunker in the Ahr valley.
=== Mass spectrometry === On an isotope-ratio mass spectrometer, the measurement of clumped isotopologues has to be conducted on intact methane molecules, instead of converting methane to CO2, H2 or H2O. High mass resolution is required to distinguish different isotopologues of very close relative molecular mass (same "cardinal mass", e.g. 13CH4 and 12CH3D (17.03465 Da (daltons) versus 17.03758 Da), 13CH3D and 12CH2D2 (18.04093 Da versus 18.04385 Da). Currently, two commercial models capable of such measurement are Thermo Scientific 253 Ultra and the Panorama by Nu Instruments.
=== Interacting Subpopulation SEIR Model === As social contacts, disease severity and lethality, as well as the efficacy of prophylactic measures may differ substantially between interacting subpopulations, e.g., the elderly versus the young, separate SEIR models for each subgroup may be used that are mutually connected through interaction links. Such Interacting Subpopulation SEIR models have been used for modeling the COVID-19 pandemic at continent scale to develop personalized, accelerated, subpopulation-targeted vaccination strategies that promise a shortening of the pandemic and a reduction of case and death counts in the setting of limited access to vaccines during a wave of virus Variants of Concern.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.